Comparative Pharmacology
Head-to-head clinical analysis: BESIVANCE versus VASOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BESIVANCE versus VASOCIDIN.
BESIVANCE vs VASOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BESIVANCE is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and leading to bacterial cell death.
Vasocidin is a combination of sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth, and prednisolone sodium phosphate, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and subsequent prostaglandin and leukotriene synthesis.
One drop instilled into the affected eye(s) three times daily for 7 days.
One drop of the ophthalmic suspension into the conjunctival sac of the affected eye(s) every 4 hours while awake and at bedtime for 7 days; duration may be extended based on clinical response.
None Documented
None Documented
Terminal half-life of approximately 1.5-2 hours in adults; prolongation in renal impairment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment.
Primarily excreted unchanged in urine (approximately 50-60%) and feces (approximately 20-30%); biliary excretion contributes to fecal elimination.
Renal: 70-80% as unchanged drug; biliary/fecal: 20-30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination